Ono Pharmaceutical (OTCMKTS:OPHLF) Hits New 12-Month High – Still a Buy?

Ono Pharmaceutical Co. (OTCMKTS:OPHLF) shares hit a new 52-week high on Thursday . The company traded as high as $14.00 and last traded at $14.00, with a volume of 200 shares trading hands. The stock had previously closed at $12.8696.

Ono Pharmaceutical Price Performance

The company has a debt-to-equity ratio of 0.11, a current ratio of 2.99 and a quick ratio of 2.50. The firm has a market cap of $6.58 billion, a price-to-earnings ratio of 20.00 and a beta of 0.24. The stock has a 50-day moving average price of $12.76 and a 200 day moving average price of $11.65.

Ono Pharmaceutical (OTCMKTS:OPHLF) last issued its quarterly earnings results on Thursday, October 30th. The company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. The firm had revenue of $876.10 million during the quarter, compared to analysts’ expectations of $790.87 million. Ono Pharmaceutical had a net margin of 9.75% and a return on equity of 6.13%.

About Ono Pharmaceutical

Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research‐based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.

One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.